The global sildenafil drug market is estimated to be valued at US$ 2.9 Bn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

SWOT Analysis

Strength: Sildenafil drug market has a large patient pool of erectile dysfunction patients globally. The drug offers effective treatment for ED and has proven efficacy. Being an established drug, it faces low development risks with high entry barriers for competitors.

Weakness: The market faces intense competition from generic manufacturers and alternate treatment options. Patent expiration of branded versions also impacts revenues of major players.

Opportunity: Emerging economies offer high growth potential owing to increasing healthcare spending and large undiagnosed population. New delivery systems andfixed-dose combinations with other drugs can boost the market size.

Threats: Stricter regulations and compliance norms may lead to delays in new product approvals. Safety issues or misuse of the drug can impact brand image negatively.

Key Takeaways:

The Global Sildenafil Drug Market Growth is expected to witness steady growth supported by rising ED prevalence, growing healthcare expenditure and availability of generic versions. The market size is estimated to reach a value of US$ 2.9 Billion by 2023 expanding at a CAGR of 6.3% during the forecast period.

Regional analysis

The Asia Pacific region dominates the global market and is projected to witness the fastest growth over the next decade. Increasing geriatric population, growing health awareness and improved access to healthcare are some key factors driving the APAC sildenafil drug market. China, India and Japan collectively account for over half of the total regional revenues owing to their huge patient bases and focus on erectile dysfunction treatment. North America is another major region for sildenafil drug makers owing to high healthcare spending and volume sales in the US.

Key players

Key players operating in the sildenafil drug market are Synutra Inc., Darling Ingredients Inc., Archer Daniels Midland Company, BASF SE, Koninklijke DSM NV, Foodchem International Corporation, Glanbia PLC, Holista, Colltech Ltd, ESM Technologies LLC, Bergstorm Nutrition Inc., and Gelita AG. Key players are focused on product development, strengthening distribution networks and adopting generic strategies to increase market share.

Explore more information on this topic, Please visit – 

https://www.zupyak.com/p/3969699/t/global-sildenafil-drug-market-growth-accelerated-by-increased-usage-to-treat-erectile-dysfunction